Article Text

Download PDFPDF
PP-025 Stability of intravitreal bevacizumab solution in polypropylene syringes in neovascular macular degeneration
  1. F Gutiérrez Nicolas1,
  2. E Sanchez Negrín2,
  3. A Santoveña Estévez2,
  4. J Nazco Casariego3,
  5. T Virgos Aller3,
  6. J Fariña Espinosa2
  1. 1Hospital Universitario de Canarias, Hospitalary Pharmacy, Santa Cruz de Tenerife, Spain
  2. 2Universidad de La Laguna, Tecnología Farmaceútica, La Laguna, Spain
  3. 3Hospital Universitario de Canarias, Farmacia Hospitalaria, La Laguna, Spain


Background Bevacizumab is used by intravitreal administration as an off-label drug to treat age-related macular degeneration and other ophthalmologic diseases.

Purpose To analyse the physicochemical stability of bevacizumab repackaged in 1-mL polypropylene syringes for intravitreal injection.

Material and methods Bevacizumab syringes were repackaged under laminar flow. Each syringe contained 200 or 900 μL (25 mg/mL). For the stability assessment at 4°C, three storage groups of 2 repacked syringes and 2 original vials were constituted for each analysis time (0, 3, 7, 14 days). For bevacizumab characterisation a HPLC consisting of a Waters pump (600 E), an autosampler (717 plus), a dual UV detector (2487) to 214 nm, as stationary phase ShodexKW804 (8.0 mm × 300 mm) column and a mobile phase (25 mM NaH2PO4·2 H2O and 300 mM NaCl pH 7) at a flow of 1 ml/min. The size distribution of particles in the samples incubated in syringes was determined by a Zetasizer system.

Results The proposed HPLC method allowed us to separate two peaks for the bevacizumab control sample, corresponding to bevacizumab monomer (mean peak) and its oligomer, with retention times of 9.8 and 8.6 min respectively. We used the evolution of the monomer peak area value to indicate the stability. For the original vials the area values remained at 100% of their initial value for 7 days storage. For repacked bevacizumab this value was maintained for 3 days. The Zetasizer particles analyser detected submicron particles whose origin could be the repacking, for the vials mean particle size (17.8 ± 4.7) nm remained constant for 15 days. For repacked syringes this value remained constant for 3 days, at day 7 we found a small% of particles with size next to 5 µm indicating probable particle contamination of unknown origin.

Conclusion Our results support the physicochemical stability for 3 days at 4°C of repackaged bevacizumab for intravitreal administration.


  1. National Investigation Project of the Ministerio de Ciencia e Innovación in Spain (SAF2010–17083)

ReferenceNo conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.